TNFRSF17 and Miyoshi myopathy: Other approach for R/R MM patients include another targeted CAR-T and bispecific antibodies etc. In MagnetisMM-1 trial, 3 of 4 pts (75%) with prior BCMA-directed therapy achieved response (1 sCR, 2 VGPR) for Elranatamab, a humanized bispecific monoclonal antibody (BsAb) that targets BCMA [25].